Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the
treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels …

In response to vessel injury (or other pathological conditions), the hemostatic process is
activated, resulting in a fibrous, cellular-rich structure commonly referred to as a blood clot …

Simple Summary Discovered more than three decades ago, the urokinase-type
plasminogen activator receptor (uPAR) has now firmly established itself as a versatile …

The extracellular matrix (ECM) is a complex and specialized three-dimensional
macromolecular network, present in nearly all tissues, that also interacts with cell surface …

Since the proposition of the pro‐invasive activity of proteolytic enzymes over 70 years ago,
several roles for proteases in cancer progression have been established. About half of the …

Cutaneous squamous cell carcinoma (cSCC) of the head and neck region is the second
most prevalent skin cancer, with metastases to regional lymph nodes occurring in 2%–5% of …

The interaction between the serine protease urokinase-type plasminogen activator (uPA)
and its glycolipid-anchored receptor (uPAR) focalizes plasminogen activation to cell …

Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …

Polymeric nanocarriers (PNCs) can be used to deliver therapeutic microRNAs (miRNAs) to
solid cancers. However, the ability of these nanocarriers to specifically target tumors remains …

The first toxin to give rise to the three‐finger protein (TFP) family was α‐bungarotoxin (α‐Bgt)
from Bungarus multicinctus krait venom. α‐Bgt was crucial for research on nicotinic …